APRE Aprea Therapeutics Inc.

34.75
+2.89  (+9%)
Previous Close 31.86
Open 31.38
Price To Book -10.31
Market Cap 729,419,945
Shares 20,990,502
Volume 105,673
Short Ratio
Av. Daily Volume 87,669
Stock charts supplied by TradingView

NewsSee all news

  1. Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  2. Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial

    BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ:APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53

  3. Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation

    BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  4. Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020

    BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  5. Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

    74% ORR, 66% CR rate in 24 evaluable MDS patientsMedian duration of follow-up is 6.4 months BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data at ASH December 9, 2019. 88% ORR, 61% CR rate.
APR-246 and azacitidine
Myelodysplastic syndromes (MDS)
Phase 3 top-line data due by the end of 2020.
APR-246 and azacitidine
TP53 mutant Myelodysplastic syndromes (MDS)
Phase 2 enrolment had been expected to be completed 1H 2020. Evaluating if there will be delays due to COVID-19.
APR-246 and azacitidine
TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
Phase 1 trial initiated 1Q 2020.
APR-246 / venetoclax and azacitidine
TP53 mutant AML
Phase 1 enrolment to commence 2H 2020.
APR-246 and venetoclax and rituximab
Chronic lymphoid leukemia (CLL) and Mantle cell lymphoma (MCL)
Phase 1/2 enrolment to commence 2H 2020.
APR-246
Solid tumors

Latest News

  1. Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  2. Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial

    BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ:APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53

  3. Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation

    BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  4. Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020

    BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  5. Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

    74% ORR, 66% CR rate in 24 evaluable MDS patientsMedian duration of follow-up is 6.4 months BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on

  6. Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando

    88% ORR, 61% CR rate by IWG criteria in 33 evaluable MDS patients8.4 months median duration of response, with 7.3 months median duration of CR in evaluable MDS patients52% of evaluable MDS patients discontinued treatment

  7. Aprea Therapeutics Reports Third Quarter 2019 Financial Results

    BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  8. Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting

    BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor

  9. Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    BOSTON, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor